30.04.2020 Novavax Inc (NVAX) Daily Analysis
Shares of Novavax (NASDAQ:NVAX) went down by 10.4% on Wednesday, and even today the shares are still low and it is trading on 18.41usd. The company did not
Yayınlanma: 1 Mayıs 2020 14:30
Güncellenme: 20 Kasım 2024 12:39
30.04.2020 Novavax Inc (NVAX) Daily Analysis
Novavax Inc (NVAX) 18.41USD ,-2.13 ,-10.39%
Shares of Novavax (NASDAQ:NVAX) went down by 10.4% on Wednesday, and even today the shares are still low and it is trading on 18.41usd. The company did not post any news inline with their vaccine or anything but what is making the stock go down is that Gilead Sciences announced their positive results from phase 3 clinical trial for Remdesivir which is a potential treatment for Covid-19. The news about the positive results of this treatment led investors to not have much confidence in Novavax if they will be successful in its potential COVID-19 vaccine. Gilead's Remdesivir has been considered the most promising potential treatment for COVID-19. Back in February, the National Institutes of Health (NIH) started a phase 3 clinical trial investigating the safety and efficacy of Remdesivir as a treatment for the coronavirus and both Gilead and the NIH announced positive results from this trial.
